In utero exposure to HIV and/or antiretroviral therapy: a systematic review of preclinical and clinical evidence of cognitive outcomes.
Adolescent
Brain
/ diagnostic imaging
Child
Child, Preschool
Cognition
/ drug effects
Female
HIV Infections
/ drug therapy
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical
/ prevention & control
Male
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
Prenatal Exposure Delayed Effects
/ physiopathology
HIV
antiretroviral therapy
brain
cognition
highly active
laboratory animal science
maternal exposure
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
31
08
2018
accepted:
15
03
2019
entrez:
16
4
2019
pubmed:
16
4
2019
medline:
14
4
2020
Statut:
ppublish
Résumé
With the increasing number of children exposed to HIV or antiretroviral therapy in utero, there are concerns that this population may have worse neurodevelopmental outcomes compared to those who are unexposed. The objective of this study was to systematically review the clinical and preclinical literature on the effects of in utero exposure to HIV and/or antiretroviral therapy (ART) on neurodevelopment. We systematically searched OVID Medline, PsycINFO and Embase, as well as the Cochrane Collaborative Database, Google Scholar and bibliographies of pertinent articles. Titles, abstracts, and full texts were assessed independently by two reviewers. Data from included studies were extracted. Results are summarized qualitatively. The search yielded 3027 unique titles. Of the 255 critically reviewed full-text articles, 25 met inclusion criteria for the systematic review. Five articles studied human subjects and looked at brain structure and function. The remaining 20 articles were preclinical studies that mostly focused on behavioural assessments in animal models. The few clinical studies had mixed results. Some clinical studies found no difference in white matter while others noted higher fractional anisotropy and lower mean diffusivity in the brains of HIV-exposed uninfected children compared to HIV-unexposed uninfected children, correlating with abnormal neurobehavioral scores. Preclinical studies focused primarily on neurobehavioral changes resulting from monotherapy with either zidovudine or lamivudine. Various developmental and behavioural changes were noted in preclinical studies with ART exposure, including decreased grooming, decreased attention, memory deficits and fewer behaviours associated with appropriate social interaction. While the existing literature suggests that there may be some neurobehavioral differences associated with HIV and ART exposure, limited data are available to substantially support these claims. More research is needed comparing neurobiological factors between HIV-exposed uninfected and HIV-unexposed uninfected children and using exposures consistent with current clinical care.
Identifiants
pubmed: 30983111
doi: 10.1002/jia2.25275
pmc: PMC6462810
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25275Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007637
Pays : United States
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Psychopharmacology (Berl). 1999 Aug;145(3):317-23
pubmed: 10494581
Neurosci Lett. 2002 Nov 22;333(2):111-4
pubmed: 12419493
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Pediatr Res. 1993 Aug;34(2):192-8
pubmed: 8233724
AJNR Am J Neuroradiol. 2005 Apr;26(4):695-701
pubmed: 15814907
Viruses. 2018 Feb 11;10(2):
pubmed: 29439467
AIDS. 2018 Nov 13;32(17):2583-2592
pubmed: 30134292
J Dev Behav Pediatr. 2010 May;31(4):346-56
pubmed: 20453582
Brain Res. 2008 Sep 26;1232:139-54
pubmed: 18674522
Neurotoxicol Teratol. 2005 Jan-Feb;27(1):169-73
pubmed: 15681130
PLoS One. 2013;8(2):e55753
pubmed: 23409035
J Int AIDS Soc. 2019 Apr;22(4):e25275
pubmed: 30983111
Neurotoxicol Teratol. 1999 Jan-Feb;21(1):29-40
pubmed: 10023799
Neurotoxicol Teratol. 1998 May-Jun;20(3):251-8
pubmed: 9638682
Neurotoxicol Teratol. 2002 Nov-Dec;24(6):773-81
pubmed: 12460660
Neuro Endocrinol Lett. 2010;31(6):747-53
pubmed: 21196923
Eur J Neurosci. 1998 Jul;10(7):2426-32
pubmed: 9749770
Neurotoxicol Teratol. 2002 Jul-Aug;24(4):529-40
pubmed: 12127899
Neurotoxicol Teratol. 1999 Jul-Aug;21(4):365-73
pubmed: 10440480
Psychopharmacology (Berl). 2001 Feb;153(4):434-42
pubmed: 11243490
Neurotoxicol Teratol. 2000 May-Jun;22(3):369-79
pubmed: 10840180
BMC Neurol. 2012 Nov 29;12:148
pubmed: 23194030
Pharmacol Biochem Behav. 2000 Nov;67(3):511-7
pubmed: 11164081
Trop Med Int Health. 2018 Jan;23(1):69-78
pubmed: 29131457
Teratology. 2001 Jan;63(1):26-37
pubmed: 11169552
Proc West Pharmacol Soc. 2004;47:46-9
pubmed: 15633610
Prog Neurobiol. 2013 Jul-Aug;106-107:1-16
pubmed: 23583307
J Pediatric Infect Dis Soc. 2016 Dec;5(suppl 1):S24-S32
pubmed: 27856673
Pharmacol Biochem Behav. 1999 Nov;64(3):479-85
pubmed: 10548259
Medicine (Baltimore). 2016 Jan;95(4):e2577
pubmed: 26825902
Environ Health Perspect. 2005 Oct;113(10):1437-46
pubmed: 16203260
AIDS. 2018 Nov 28;32(18):2749-2757
pubmed: 30289800
Pediatrics. 2017 Oct;140(4):
pubmed: 28912368
Neurotoxicol Teratol. 2005 Jul-Aug;27(4):599-608
pubmed: 15994058
Pediatrics. 2018 Feb;141(2):
pubmed: 29374109
Neurotoxicology. 1999 Feb;20(1):17-25
pubmed: 10091855
Pediatr Infect Dis J. 2015 Sep;34(9):e211-6
pubmed: 26090574
Front Neuroanat. 2017 Sep 29;11:88
pubmed: 29033797
J Magn Reson Imaging. 2005 May;21(5):503-11
pubmed: 15834918
Neurotoxicol Teratol. 2004 Jan-Feb;26(1):65-71
pubmed: 15001215